SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001136261-18-000259
Filing Date
2018-10-09
Accepted
2018-10-09 16:34:26
Documents
7
Period of Report
2018-07-27
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A body8ka.htm 8-K/A 16417
2 CONSENT exh23-1.htm EX-23.1 1379
3 CONSET exh23-2.htm EX-23.2 1423
4 AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF OREXIGEN THERAPEUTICS, INC. exh99-2.htm EX-99.2 497093
5 UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS OF OREXIGEN THERAPEUTICS, INC. exh99-3.htm EX-99.3 241813
6 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION exh99-4.htm EX-99.4 290891
7 LOGO image1904.jpg GRAPHIC 6415
  Complete submission text file 0001136261-18-000259.txt   1059184
Mailing Address 10 NORTH PARK PLACE SUITE 201 MORRISTOWN NJ 07960
Business Address 10 NORTH PARK PLACE SUITE 201 MORRISTOWN NJ 07960 (862) 260-8457
PERNIX THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001024126 (see all company filings)

IRS No.: 330724736 | State of Incorp.: MD | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-14494 | Film No.: 181114044
SIC: 2834 Pharmaceutical Preparations